162536-72-3

Upstream product

• 98760-08-8 (1-oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester 
• 103127-56-6 [S-(R*,R*)]-(1-oxiranyl-2-phenylethyl)-carbamic acid 1,1-dimethylethyl ester 
• 98760-08-8 (2R,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1,2-epoxy-4-phenylbutane 
• 165727-45-7 tert-butyl ((2S,3S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate 
• 102123-74-0 (S)-tert-butyl (4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate 
• 67729-36-6 Boc-Phe-O-COO-isoBu 
• 60398-41-6 (3S)-tert-butyl 1-benzyl-3-diazo-2-oxopropylcarbamate 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 

Downstream Products

• 165331-67-9 [(3S,2R)-3-amino-2-hydroxy-4-phenylbutyl]azide 
• 1238072-01-9 (4S,5R)-5-azidomethyl-4-benzyl-3-methyl-oxazolidin-2-one 
• 849411-00-3 N-[(1S,2R)-3-azido-1-benzyl-2-hydroxypropyl]-3-[(benzylsulfonyl)(methyl)amino]benzamide 
• 162536-74-5 ((1S,2R)-3-Amino-1-benzyl-2-methoxy-propyl)-carbamic acid tert-butyl ester 
• 288296-33-3 {(1S,2R)-3-[(Benzo[1,3]dioxole-5-sulfonyl)-(4-dibenzylamino-2,2-dimethyl-butyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester 
• 288292-38-6 {(1S,2R)-3-[(7-Amino-2,2-dimethyl-heptyl)-(benzo[1,3]dioxole-5-sulfonyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester 
• 288296-37-7 {(1S,2R)-3-[(Benzo[1,3]dioxole-5-sulfonyl)-(6-cyano-2,2-dimethyl-hexyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester 
• 288291-99-6 (3R,3aS,6aR)-hexahydro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-3-[6-amino-2,2-dimethylhexyl][(3,4-methylenedioxyphenyl)sulfonyl]amino-2-hydroxypropyl)carbamate 
• 288296-75-3 (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl N-(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(5-cyano-2,2-dimethylpentyl)amino]-1-benzyl-2-hydroxypropylcarbamate 
• 288292-12-6 {(1S,2R)-3-[(5-Amino-2,2-dimethyl-pentyl)-(benzo[1,3]dioxole-5-sulfonyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester 
• 681028-79-5 {(1S,2R)-3-[(Benzo[1,3]dioxole-5-sulfonyl)-(6-chloro-2,2-dimethyl-hexyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester 
• 288291-55-4 {(1S,2R)-3-[(Benzo[1,3]dioxole-5-sulfonyl)-(4-cyano-2,2-dimethyl-butyl)-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)hexahydro-furo[2,3-b]furan-3-yl ester 
• 288292-43-3 (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl N-(1S,2R)-1-benzyl-3-[(3-aminophenylsulfonyl)(5-amino-2,2-dimethylpentyl)amino]-2-hydroxypropylcarbamate 

Relevant academic research and scientific papers

INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS

The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.

4-ARYL-BUTANE-1,3-DIAMIDES

The invention relates to compound of the formula (1) in which the substituents are as defined in the specification; m free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS

The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.

BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amo

BETA-SECRETASE INHIBITING COMPOUNDS

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amount of the same.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE

The present invention relates to novel derivatives of sulfone amide of Formula 1 as defined in this disclosure which inhibit the activity of BACE (or beta-secretase). These sulfone amide derivatives are useful for the treatment and prevention of Alzheimer's disease and related diseases caused by production of beta-amyloid, by inhibiting the activity of BACE.

Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains

A novel series of P1′ chain-extended arylsufonamides was synthesiszed and evaluated for wild-type HIV protease inhibitory activity and in vitro antiviral activity against wild type virus and two protease inhibitor-resistant mutant viruses. All of the comp

Retrocarbamate protease inhibitors

The invention discloses compounds of the formula STR1 are disclosed as HIV protease inhibitors.

Synthesis and absolute configuration of (+)-2,3,3-trimethyl-2-hydroxybutanoic acid

The absolute configuration of (+)-2,3,3-trimethyl-2-hydroxybutanoic acid, a key intermediate in the synthesis of the HIV-protease inhibitor 1a (isomer A), has been confirmed as (R) on the basis of X-ray analysis.